Détails du produit
- ProductSizeAmountActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable)2.5 mg2.5 × 10⁷ beadsActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable)10 mg (2.5 mg × 4)1.0 × 10⁸ beads
Product Show

This product can be directly isolated using conventional column-free magnetic stand (eg. Cat. MB-01/ MB-02/ MB-03/ MB-04). Please note that due to its micron-scale size, it is not compatible with commercially available column-based (M/D/L) magnetic separation systems.
Features
- Sterility
- Endotoxin content ≤0.002 EU/μg
- Mycoplasma
- Batch-to-batch consistency
Product Description
ActiveMax® Human CD19 μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human CD19 protein expressed from human 293 cells (HEK293) and contains AA Pro 20 - Pro 278 (Accession # P15391-1).
ActiveMax® Human CD19 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.
Compared to MBS-C002, this product demonstrates superior stability and a longer shelf life, ensuring consistent and reliable performance over extended periods.Application
ActiveMax® Human CD19 μBeads, premium grade (for cells) are designed to stimulate in vitro CD19-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human CD19 antigen. It can be used as follows:
Evaluating the characteristics of CAR-T cells or UCAR-T cells.
In vitro expansion of CD19-specific CAR-T cells or UCAR-T cells.
In vitro enrichment of CD19-specific CAR-T cells or UCAR-T cells.Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 12 months under sterile conditions after reconstitution. 2-8°C for 2 week under sterile conditions after reconstitution.
Please protect from light and avoid repeated freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
Sterility
Negative
Endotoxin
Less than 2 EU per mg by the LAL method / rFC method.
Mycoplasma
Negative
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Lyophilized in PBS with 0.1% rHSA, pH 7.4. Trehalose is added as protectant before lyophilization.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
FACS Data

Assay of human CD19 protein on the μBeads surface by Flow cytomtry. The human CD19 conjugated on the μBeads (Cat. No. MBS-C035) surface were fluorescently stained using PE labeled anti-human CD19 antibody and analyzed by flow cytometry (QC tested).
Protocol
Application Data

ActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable) (Cat. No. MBS-C035) can activate CD19-specific CAR-T cells by detecting the secretion of IFN- γ in vitro (Routinely tested).

Enrichment of Anti-CD19+ CAR-T Cells Using ActiveMax® Human CD19 μBeads, Premium Grade (for cells, Super stable).
For 2.5 × 10⁶ Anti-CD19 CAR-T cells with initial positivity rates of 59.05% (donor 1)and 31.18% (donor 2), respectively, significant enrichment was achieved using ActiveMax® Human CD19 μBeads, Premium Grade (for cells, Super stable) (Cat. No. MBS-C035) at Beads : cells ratios of 0.2:1, 1:1, and 5:1. At a Beads : cells ratio of 5:1, the enrichment efficiency reached 87% for the donor 1 and 95% for the donor 2.
Beads enrichment efficiency=1-(untouched cells * ratio of CD19 CAR-T )/(Initial cells * ratio of CD19 CAR-T) * 100%.
Avis des utilisateurs Publier un commentaire

Progrès de frontière
- Nom anglais:
B-lymphocyte antigen CD19
- Catégorie:
- Nombre de médicaments répertoriés:
14 Détails
- Nombre de médicaments cliniques:
435 Détails
- Étape de développement la plus élevée:
Approved



















